The Board of Directors of 3B BlackBio Dx Limited approved the unaudited standalone and consolidated financial results for the first quarter of FY27 (ended June 30, 2026) on August 13, 2026. The company reported a 13% year-on-year increase in consolidated net profit after tax (PAT) to ₹89.8 crore, while revenue from operations declined by 6% to ₹334.9 crore.

Standalone net profit also grew 13% year-on-year to ₹141.1 crore, supported by a significant rise in other income. The company’s agrochemical business remains seasonal, with performance subject to weather conditions and cropping patterns, according to management disclosures.

Financial Performance

Consolidated total income stood at ₹396.3 crore for the quarter, down from ₹455.8 crore in the corresponding quarter of FY26. This decline was primarily driven by lower other income, which fell to ₹61.4 crore from ₹101.5 crore in the prior year period. Revenue from operations decreased to ₹334.9 crore from ₹354.3 crore.

Total expenses were contained at ₹264.1 crore, compared to ₹309.4 crore in Q1FY26. Depreciation and amortization expenses dropped sharply to ₹134.4 crore from ₹389.1 crore in the previous quarter, contributing to improved profitability margins despite lower top-line growth.

Note: Consolidated PAT for Q1FY26 includes non-controlling interests adjustments; standalone figures reflect parent entity performance.

Segment-wise Results

The diagnostic kits segment continues to dominate the company’s financial performance. It contributed ₹320.6 crore in revenue, accounting for approximately 96% of total consolidated income. The segment generated a profit before interest and tax of ₹133.2 crore.

In contrast, the agrochemicals segment reported minimal revenue of ₹14.3 crore against ₹22.7 crore in the same quarter last year, reflecting its seasonal nature. The segment recorded a near-breakeven result with a profit of just ₹0.03 lakh.

What the Numbers Show

A notable divergence exists between standalone and consolidated profitability. While standalone PAT increased by 13% year-on-year, consolidated PAT attributable to owners of the parent declined significantly when comparing basic EPS figures (₹10.48 vs ₹14.76). This discrepancy highlights the impact of subsidiary performance and non-controlling interests on group-level results. Additionally, the sharp reduction in depreciation expenses—from ₹389.1 crore in Q4FY26 to ₹134.4 crore in Q1FY27—suggests potential changes in asset base or accounting treatments that warrant monitoring in subsequent quarters.

Corporate Actions

The board appointed M/s Sanjay Kasliwal & Associates, Cost Accountants & Social Auditor based in Bhopal, as the Cost Auditor for FY27. The appointment complies with Section 148 of the Companies Act, 2013. Shareholders will ratify the remuneration at the upcoming Annual General Meeting.

Baheti & Co., the statutory auditors, completed their limited review of the financial statements. The audit report confirmed no material misstatements in compliance with SEBI Listing Regulations and Ind AS standards.

Promoter Dhirendra Dubey increased his shareholding in 3b blackbio dx by purchasing 1,000 equity shares on June 24, 2026. The transaction was executed through the open market, raising the promoter's stake to 8.45% of the total voting capital.

The disclosure was submitted under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Prior to this acquisition, Dubey held 7,24,098 shares, which accounted for 8.44% of the company's equity.

Shareholding Details

The following table outlines the changes in the promoter's shareholding following the transaction:

The company's equity share capital remains at Rs 8,58,26,700, consisting of 85,82,670 equity shares of Rs 10 each. There were no changes to the encumbered shares or convertible securities held by the acquirer.